Lupin Limited announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology 2026 Annual Meeting. The conference is being held from May 29 to June 2, 2026, in Chicago, Illinois. The data were shared through an abstract published on the ASCO website.
The abstract, titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors," was published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track. LNP8701 is an orally administered investigational SOS1 inhibitor designed to block SOS1-mediated RAS activation, limiting oncogenic signaling that promotes tumor growth.
Results from the ongoing first-in-human study indicate that LNP8701 was well tolerated with a desirable safety and pharmacokinetics profile and favorable anti-tumor activity. Two patients completed LNP8701 monotherapy for 12 cycles, equivalent to one year, and one patient completed 14 cycles with stable disease. Current data suggest LNP8701 is safe and well-tolerated across all tested dosing levels.
Vinita Gupta, Chief Executive Officer of Lupin, said the findings point to the emerging potential of LNP8701 and mark progress in Lupin's pursuit of novel therapies for difficult-to-treat cancers.
Lupin will continue to study LNP8701 in a Phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination regimen. The clinical trial is registered under number CTRI/2024/08/072373.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.